Hyperglycemia occurs frequently during first-line non-Hodgkin lymphoma (NHL) treatment with either R-CHOP or DA-EPOCH-R chemotherapy regimens, according to a retrospective study involving 160 individuals. This is the case even in patients without diabetes. Participants had NHL and underwent R-CHOP or DA-EPOCH-R. Investigators looked at hyperglycemia incidence, as well as how frequently chemotherapy was altered in those with and without hyperglycemia. They also assessed overall survival. Among the results:
- 47% of all patients had ≥1 hyperglycemic episode.
- Those with hyperglycemia tended to have their chemotherapy altered.
- International prognostic index ≥3 and chemotherapy alteration were linked with decreased overall survival.
The authors noted that baseline pre-PET scan fasting blood glucose of ≥100 mg/dL appears to predict hyperglycemia during therapy.
Lamar Z, Dothard A, Kennedy L, et al. Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration—a retrospective study. [Published online ahead of print December 18, 2017]. Leuk Lymphoma. doi:10.1080/10428194.2017.1410889.